Bioverativ's extended half-life therapies, Eloctate [Antihemophilic Factor VIII (Recombinant), Fc Fusion Protein] and Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] for the treatment of hemophilia A
and B, respectively, represented the first major advancements in the hemophilia market in nearly two decades when launched.
Classical hemophilia a
study of 236 cases from 212 unrelated families.
The BHAP grants will support research into a broad range of projects, including anxiety among female carriers of hemophilia, FVIII splicing-switching molecules for tailored hemophilia A
therapies as well as the assessment of therapeutic relationships in hemophilia care.
Desmopressin (DDAVP) is a man-made hormone used to treat people who have mild hemophilia A
Many people affected by hemophilia a
life-long condition show strength and resilience each day, with support from caregivers and friends who make a difference in their lives.
The WHO says hemophilia A
is the most common form, referred to as classical hemophilia, which is the result of a deficiency in clotting factor 8.
Majority of patients are of hemophilia A
(FVIII deficiency) and only a handful cases of hemophilia B (FIX deficiency) are seen.
While antibody develops against the factor administered in approximately 15-25% of the patients with severe hemophilia A
, this rate is much lower in patients with hemophilia B (3%).
In 2014, the 9MM had 60,671 diagnosed prevalent cases of hemophilia A
and hemophilia B, around 28% of which occurred in the US.
It also reviews key players involved in the therapeutic development for Hemophilia A
and special features on late-stage and discontinued projects.
In hemophilia A
(classic hemophilia), the most common type, which accounts for 90 percent of all hemophilia cases, factor VIII (antihemophilic factor) is deficient.
(known as factor VIII deficiency) is the most common inherited coagulation factor defect in dogs.